Abstract
Micropulse Transscleral diode laser cyclophotocoagulation (MP-TSCPC) is an established method of treatment for refractory glaucoma. This study evaluates the efficacy in terms of reduction in intraocular pressure and/or treatment amount, and safety and side effects of the ciliary bodies using a subthreshold laser with a duty cycle of 31.3% with Supra 810 nm Subliminal Quantel Medical, at one year in patients with refractory glaucoma.
Highlights
Glaucoma is a progressive optic neuropathy that can lead to vision loss if left untreated [1]
Our study shows a reduction in intraocular pressure (IOP) and pain at one year in refractory glaucoma patients treated with subthreshold transscleral cyclophotocoagulation (SubCyclo) with a 31.3% duty cycle, 80s per hemisphere and 2W of power
Despite the retrospective observational nature of the study and the small population size, we believe that this technique is useful in the management of refractory glaucoma
Summary
Glaucoma is a progressive optic neuropathy that can lead to vision loss if left untreated [1]. Treatment involves lowering intraocular pressure to delay disease progression [2], either through local medical treatment (eye drops), surgical treatment (filtering surgery) or physical means (lasers). A new subthreshold diode laser therapy involving the treatment of the ciliary bodies has been developed: An infrared laser (810 nm) that targets the ciliary processes to reduce aqueous humour secretion [3]. The objective of our study was to evaluate its efficacy in terms of reduction in intraocular pressure and/or number of eye drops applied, as well as to assess the safety and side effects of the subliminal diode treatment of the ciliary bodies with a subthreshold laser at one year in patients with refractory glaucoma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have